# Efficacy and Safety Study of Mepolizumab in Subjects With Moderate to Severe Atopic Dermatitis

> **NCT03055195** · PHASE2 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 34 (actual)

## Conditions studied

- Dermatitis, Atopic

## Interventions

- **DRUG:** Mepolizumab 100 mg
- **DRUG:** Placebo matching mepolizumab

## Key facts

- **NCT ID:** NCT03055195
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-03-21
- **Primary completion:** 2017-12-06
- **Final completion:** 2017-12-06
- **Target enrollment:** 34 (ACTUAL)
- **Why stopped:** Study reached pre-determined futility criteria following interim analysis. No safety concerns were noted.
- **Last updated:** 2020-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03055195

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03055195, "Efficacy and Safety Study of Mepolizumab in Subjects With Moderate to Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03055195. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*